UNCY
What one share of Unicycive Therapeutics holds
Pharmaceutical Preparations
Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable
Unicycive Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.56 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.23 |
| Cash and investments | $2.21 |
| Book value | $1.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$2.66 | — | −$1.72 | — | −$3.14 |
| 2021 | — | −$8.58 | $0.02 | −$4.96 | — | $10.99 |
| 2022 | $0.63 | −$11.99 | $0.00 | −$10.40 | — | −$0.31 |
| 2023 | $0.28 | −$12.80 | $0.00 | −$7.46 | — | −$1.10 |
| 2024 | — | −$5.65 | $0.01 | −$4.28 | — | $0.65 |
| 2025 | — | −$1.67 | $0.00 | −$1.97 | — | $1.37 |